CombiGene
2,54
SEK
+3,67 %
Mindre end 1K følgere
COMBI
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+3,67%
+5,83%
-0,78%
+6,72%
-9,29%
-22,32%
-66,36%
-76,67%
-97,35%
CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.
Læs mereMarkedsværdi
50,3 mio. SEK
Aktieomsætning
611,75 t SEK
Omsætning
330 t
EBIT %
-14.309,09 %
P/E
-
Udbytteafkast, %
-
Finanskalender
12.6
2025
Generalforsamling '25
22.8
2025
Delårsrapport Q2'25
13.2
2026
Årsrapport '25
Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Västra Hamnen Market Focus: CombiGene: Making place for new ventures
Year-end report January-December 2024 CombiGene AB (Publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools